January 17th 2025
Admissions to the hospital for fever were reduced in pediatric patients with medium-risk ALL receiving intravenous immunoglobulin, a potentially useful finding to help prevent infections in vulnerable patients.
CDC, FDA Announce 77,000 Additional Doses for Nirsevimab as Infant Treatment of RSV
November 22nd 2023Additional doses for the prophylaxis of respiratory syncytial virus will immediately be distributed to physicians and hospitals through commercial channels and the Vaccines for Children Program.
Read More
CDC Issues Alert to Address Shortage of RSV Treatment Nirsevimab
October 24th 2023Nirsevimab-alip (Beyfortus; Sanofi and AstraZeneca) is a monoclonal antibody approved to prevent against respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants under 8 months of age born during or entering their first RSV season.
Read More
Cognitive Training Programs Have No Long-Term Benefit for Children Born Very Preterm
September 13th 2023Children born at 24- through 34-weeks’ gestation could have neurobehavioral problems and developmental dysfunctions, including language, executive function, attention, and behavioral disorders.
Read More